Could a Cholesterol-Lowering cream replace surgery for eyelid bumps?
NCT ID NCT07662785
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a cream containing simvastatin (a cholesterol-lowering drug) can safely shrink yellow cholesterol deposits on the eyelids, called xanthelasma. Thirty adults will apply either the active cream or a placebo nightly for 24 weeks, then everyone gets the active cream for another 24 weeks. The goal is to see if this non-invasive option works without the scarring or recurrence risks of current treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Topical simvastatin 2% cream
- What this could lead to
- If it works, this could offer a non-invasive, scar-free treatment for xanthelasma, replacing surgery or lasers.
- What could go wrong
- This is a small, early-phase pilot study with only 30 participants. The cream may not shrink the deposits, or could cause irritation. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years or older * Clinical diagnosis of xanthelasma palpebrarum confirmed by a study investigator * At least one measurable periocular xanthelasma lesion * No procedural treatment to the study lesion(s) within the past 3 months, including excision, laser, cryotherapy, chemical cautery/trichloroacetic acid, electrocautery, or radiofrequency * Capacity to provide informed consent * Willingness to avoid other treatments for xanthelasma during the study Exclusion Criteria: * Known allergy or sensitivity to any study cream ingredient * Active periocular inflammatory disease * Use of topical eyelid treatments within the past 4 weeks, including topical corticosteroids, retinoids, acid peels, depigmenting agents, compounded creams, or over-the-counter eye creams containing active ingredients * Pregnancy or breastfeeding * Participation in another interventional clinical trial * Current unstable systemic lipid-lowering therapy * Initiation of, or dose change to, oral statin therapy within the past 8 weeks * Any condition judged by the investigator to make participation unsafe
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Xanthelasma palpebrarum are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.